Substituted phenidates: Difference between revisions
>Unity m Grammatics |
>Larnaca |
||
| (38 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
[[File: | {{headerpanel|{{stub}}}} | ||
'''Substituted phenidates''' (also known as '''phenidates''') | [[File:Substituted_phenidate.svg|thumb|right|301px||Generic structure of a phenidate molecule.]] | ||
'''Substituted phenidates''' (also known as '''phenidates''') refer to a class of compounds that predominantly produce traditional [[stimulant]] effects when [[administered]]. A substituted phenidate may be defined as an ester of ritalinic acid and its analogs. | |||
==Chemistry== | ==Chemistry== | ||
| Line 7: | Line 8: | ||
==Pharmacology== | ==Pharmacology== | ||
{{pharmacology}} | {{pharmacology}} | ||
Substituted phenidates primarily act as [[reuptake inhibitors]] of the [[monoamine]] [[neurotransmitters]] [[dopamine]], [[norepinephrine]], and to a much lesser degree, [[serotonin]]. One study found that all substituted phenidates inhibited the norepinephrine and dopamine reuptake transporters 4 to >1,000-fold more potently than the serotonin transporter.{{ | Substituted phenidates primarily act as [[reuptake inhibitors]] of the [[monoamine]] [[neurotransmitters]] [[dopamine]], [[norepinephrine]], and to a much lesser degree, [[serotonin]]. One study found that all substituted phenidates inhibited the norepinephrine and dopamine reuptake transporters 4 to >1,000-fold more potently than the serotonin transporter.<ref>{{cite journal | vauthors=((Luethi, D.)), ((Kaeser, P. J.)), ((Brandt, S. D.)), ((Krähenbühl, S.)), ((Hoener, M. C.)), ((Liechti, M. E.)) | journal=Neuropharmacology | title=Pharmacological profile of methylphenidate-based designer drugs | volume=134 | pages=133–140 | date= May 2018 | url=https://linkinghub.elsevier.com/retrieve/pii/S0028390817303878 | issn=00283908 | doi=10.1016/j.neuropharm.2017.08.020}}</ref> | ||
== List of substituted phenidates == | == List of substituted phenidates == | ||
| Line 42: | Line 43: | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Phenethylamines]] | *[[Phenethylamines]] | ||
*[[Substituted amphetamine]] | *[[Substituted amphetamine]] | ||
| Line 48: | Line 48: | ||
*[[Stimulants]] | *[[Stimulants]] | ||
[[Category:Phenidate]] | ==External links== | ||
* [https://en.wikipedia.org/wiki/List_of_methylphenidate_analogues List of methylphenidate analogues (Wikipedia)] | |||
==Literature== | |||
* Luethi, D., Kaeser, P. J., Brandt, S. D., Krähenbühl, S., Hoener, M. C., & Liechti, M. E. (2017). Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.08.020 | |||
==References== | |||
<references /> | |||
[[Category:Chemical class]] | |||
[[Category:Phenidate|*]] | |||
Latest revision as of 01:10, 10 April 2025
 |
This article is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
Substituted phenidates (also known as phenidates) refer to a class of compounds that predominantly produce traditional stimulant effects when administered. A substituted phenidate may be defined as an ester of ritalinic acid and its analogs.
Chemistry
Substituted phenidates are a chemical class based upon the molecule methylphenidate. The molecular structure of methylphenidate is comprised of a phenethylamine core with a carbon chain substitution at the Rα position that links to the RN position, forming a piperidine ring. It also includes a substitution at the Rβ position of methyl acetate.
Pharmacology
 |
This pharmacology section is incomplete. You can help by adding to it. |
Substituted phenidates primarily act as reuptake inhibitors of the monoamine neurotransmitters dopamine, norepinephrine, and to a much lesser degree, serotonin. One study found that all substituted phenidates inhibited the norepinephrine and dopamine reuptake transporters 4 to >1,000-fold more potently than the serotonin transporter.[1]
List of substituted phenidates
| Compound | R3 | R4 | RO | Structure |
|---|---|---|---|---|
| Methylphenidate | H | H | CH3 | 
|
| Ethylphenidate | H | H | CH2CH3 | 
|
| Isopropylphenidate | H | H | CH(CH3)2 | 
|
| Propylphenidate | H | H | CH2CH2CH3 | 
|
| 4-Methylmethylphenidate | H | CH3 | CH3 | 
|
| 3,4-CTMP | Cl | Cl | CH3 | 
|
| 4F-MPH | H | F | CH3 | 
|
| 4F-EPH | H | F | CH2CH3 | 
|
| Methylnaphthidate (HDMP-28) | CH=CH- | CH=CH- | CH3 | 
|
| Ethylnaphthidate (HDEP-28) | CH=CH- | CH=CH- | CH2CH3 | 
|
See also
External links
Literature
- Luethi, D., Kaeser, P. J., Brandt, S. D., Krähenbühl, S., Hoener, M. C., & Liechti, M. E. (2017). Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.08.020
References
- ↑ Luethi, D., Kaeser, P. J., Brandt, S. D., Krähenbühl, S., Hoener, M. C., Liechti, M. E. (May 2018). "Pharmacological profile of methylphenidate-based designer drugs". Neuropharmacology. 134: 133–140. doi:10.1016/j.neuropharm.2017.08.020. ISSN 0028-3908.